A case report of anaphylaxis caused by initial administration of rasburicase resulting in death just before the treatment of diffuse large B cell lymphoma

Author:

Utsu Yoshikazu1,Kaneda Natsuho1,Kawakami Makio1,Masuda Shin-ichi1,Arai Hironori1,Shimoji Sonoko1,Matsumoto Rena1,Tsushima Takafumi1,Tanaka Kazusuke1,Matsuo Kosuke1,Kimeda Chiharu1,Konno Shiho1,Aotsuka Nobuyuki1

Affiliation:

1. Japanese Red Cross Narita Hospital

Abstract

Abstract Background: Rasburicase has potent efficacy in controlling uric acid and is widely used to prevent tumor lysis syndrome in high-risk patients owing to its low toxicity profile. However, the safety of rasburicase re-administration has not been established due to the risk of anaphylaxis mediated by antibody production. However, reports of such reactions upon the initial administration of rasburicase are scarce. Case presentation: A 71-year-old Japanese female who had been diagnosed with diffuse large B cell lymphoma with a large tumor burden experienced anaphylactic shock leading to death that occurred upon initial administration of rasburicase just before the chemotherapy. The patient had several unfavorable characteristics that resulted in a fatal outcome, including a predisposition to allergies. Moreover, there was a large tumor in the posterior mediastinum that, although it would not cause a significant issue under normal circumstances, could severely impact hemodynamics if the patient entered into a state of shock. Chest compressions during cardiopulmonary resuscitation resulted in crushing of the tumor. The pre-and postmortem examination revealed that the cause of death was a cascade of events starting with anaphylaxis-induced distributive shock leading to obstructive shock due to collapse of the heart, which was compressed by the tumor. This was further compounded by massive bleeding from the tumor and tension hemothorax, resulting in circulatory collapse. Conclusions: Anaphylaxis can lead to lethal outcomes when unfavorable conditions overlap. Clinicians need to carefully assess the indication for rasburicase, considering both the risk of tumor lysis syndrome and the patient’s background risks simultaneously.

Publisher

Research Square Platform LLC

Reference20 articles.

1. 1. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97(10):2998–3003.

2. 2. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K et al: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003, 21(23):4402–4406.

3. 3. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH: Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005, 19(1):34–38.

4. 4. Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, Klein T, Luzzatto L, Clinical Pharmacogenetics Implementation C: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther 2014, 96(2):169–174.

5. 5. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008, 26(16):2767–2778.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3